Synthetic process for anticancer drug fluorapacin and trisulfide derivatives
The invention provides a synthetic and manufacturing process for the preparation of the anticancer drug, fluorapacin, bis(4-fluorobenzyl)trisulfide, and related trisulfide derivatives on large scale. Also provided are processes for the purification and isolation of fluorapacin having high purity and improved stability.
1. A process for preparing a product of formula (I),
R—CH 2 —S—S—S—CH 2 —R (I),
said process comprising:
a) providing a solution of N-(trimethylsilyl)imidazole in an organic solvent;
b) adding neat sulfur dichloride to said solution to provide a reaction mixture comprising diimidazolylsulfide; and
c) without isolation, contacting the diimidazolylsulfide with a thiol reagent of formula RCH 2 SH to provide the product of formula (I);
d) isolation of the product of formula (I); and
e) purification of the isolated product by recrystallization from at least one crystallization solvent, wherein the product of formula (I) is a crystalline product; and
wherein R is an optionally substituted aryl or an optionally substituted heteroaryl group.
2. The process of claim 1 , wherein each R group is an optionally substituted phenyl.
3. The process of claim 1 , wherein each R group is (4-fluoro)phenyl.
4. A process for preparing a product of formula (II),
said process comprising:
a) providing a solution of N-(trimethylsilyl)imidazole in an organic solvent;
b) adding neat sulfur dichloride to said solution to provide a reaction mixture comprising diimidazolylsulfide;
c) without isolation, contacting the diimidazolylsulfide with a thiol reagent of formula (4-F—C 6 H 4 )CH 2 SH, to provide the product of formula (II);
d) isolation of the product of formula (II); and
e) purification of the isolated product by recrystallization from at least one crystallization solvent, wherein the product of formula (II) is a crystalline product; and
wherein the crystalline product has ≧98% purity.
5. The process of claim 4 , wherein the organic solvent in step a) comprises a halogenated solvent.
6. The process of claim 4 , wherein the organic solvent in step a) comprises a mixture of hexanes and dichloromethane.
7. The process of claim 4 , wherein the organic solvent in step a) is a mixture of hexanes and dichloromethane having a ratio of about 3:1.
8. The process of claim 4 , wherein the neat sulfur dichloride in step b) is added over about 1 hour at room temperature.
9. The process of claim 4 , wherein step c) further comprises cooling the reaction mixture to about 0° C. prior to contacting the diimidazolylsulfide with the thiol reagent.
10. The process of claim 4 , wherein the thiol reagent in step c) is provided as a solution in an organic solvent.
11. The process of claim 4 , wherein the thiol reagent in step c) is added over about 1 hour as a solution in an organic solvent comprising hexanes and dichloromethane.
12. The process of claim 9 , wherein the reaction mixture is maintained at a temperature of about 0° C. while the thiol reagent is added over about 1 hour as a solution in an organic solvent comprising hexanes and dichloromethane.
13. The process of claim 4 , wherein the N-(trimethylsilyl)imidazole in step a) is provided in a ratio of about 1.8 to about 2.3 molar equivalents relative to the amount of sulfur dichloride in step b).
14. The process of claim 4 , wherein the N-(trimethylsilyl)imidazole in step a) is provided in a ratio of about 1.9 to about 2.1 molar equivalents relative to the amount of sulfur dichloride in step b).
15. The process of claim 4 , wherein the thiol reagent in step c) is provided in a ratio of about 1.8 to about 2.3 molar equivalents relative to the amount of sulfur dichloride in step b).
16. The process of claim 4 , wherein the thiol reagent in step c) is provided in a ratio of about 1.9 to about 2.1 molar equivalents relative to the amount of sulfur dichloride in step b).
17. The process of claim 4 , wherein step d) comprises filtration of the reaction mixture and an aqueous extractive workup.
18. The process of claim 4 wherein the at least one crystallization solvent is hexanes.
19. The process of claim 18 wherein the isolated product from step d) is dissolved in hexanes at a temperature ≦60° C. to provide a hot solution, the hot solution is filtered to provide a filtrate, and the filtrate is maintained at room temperature until crystallization occurs to provide a crystalline product.
20. A process for preparing crystalline fluorapacin having ≧98% purity, said process comprising:
a) dissolving crystalline fluorapacin in hexanes at a temperature ≦60° C. to provide a hot solution;
b) filtration of the hot solution to give a filtrate, and warming the filtrate if necessary to provide a clear solution;
c) maintaining the solution at a desired temperature until crystallization occurs, to provide a crystalline product;
d) isolation of the crystalline product, to provide crystalline fluorapacin having ≧98% purity.
21. The process of claim 20 , wherein step a) is conducted at a temperature ≧25° C. and ≦60° C.
22. The process of claim 20 , wherein the solution in step c) is maintained at about room temperature for about 24 hours.
23. The process of claim 20 , further comprising:
e) recrystallization of the crystalline fluorapacin from step d) from hot anhydrous ethanol at a temperature ≦60° C. and gradually cooled to room temperature to provide a crystalline product; and
f) isolation of the crystalline product, to provide crystalline fluorapacin having ≧99.5% purity.
24. The process of claim 23 , wherein step e) is conducted under conditions of constant humidity and constant temperature.
25. A process for preparing a fluorapacin drug standard, said process comprising:
a) dissolving crystalline fluorapacin in hexanes at a temperature ≦60° C. to provide a hot solution;
b) filtration of the hot solution to provide a filtrate, and warming the filtrate if necessary to provide a clear solution;
c) maintaining the solution at a desired temperature until crystallization occurs to provide a crystalline product;
d) isolation of the crystalline product, to provide crystalline fluorapacin having ≧98% purity;
e) recrystallization of the crystalline fluorapacin from step d) from hot anhydrous ethanol at a temperature ≦60° C. and gradually cooled to room temperature under conditions of constant humidity and constant temperature to provide a crystalline product; and
f) isolation of the crystalline product, to provide the fluorapacin drug standard having ≧99.5% purity.
26. The process of claim 25 , further comprising drying the crystalline product isolated in step d) and/or step f) under vacuum at room temperature for about 24 hours.